Target Price | $5.00 |
Price | $0.66 |
Potential |
661.62%
register free of charge
|
Number of Estimates | 5 |
5 Analysts have issued a price target Sangamo Therapeutics, Inc. 2026 .
The average Sangamo Therapeutics, Inc. target price is $5.00.
This is
661.62%
register free of charge
$10.00
1,423.23%
register free of charge
$2.00
204.65%
register free of charge
|
|
A rating was issued by 7 analysts: 5 Analysts recommend Sangamo Therapeutics, Inc. to buy, 2 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Sangamo Therapeutics, Inc. stock has an average upside potential 2026 of
661.62%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 57.80 | 76.98 |
67.20% | 33.19% | |
EBITDA Margin | -155.31% | 28.58% |
197.18% | 118.40% | |
Net Margin | -180.44% | -69.88% |
0.95% | 61.27% |
6 Analysts have issued a sales forecast Sangamo Therapeutics, Inc. 2025 . The average Sangamo Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an Sangamo Therapeutics, Inc. EBITDA forecast 2025. The average Sangamo Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
7 Sangamo Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Sangamo Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -0.49 | -0.25 |
66.89% | 48.98% | |
P/E | negative | |
EV/Sales | 1.77 |
7 Analysts have issued a Sangamo Therapeutics, Inc. forecast for earnings per share. The average Sangamo Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Sangamo Therapeutics, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
RBC Capital |
Locked
➜
Locked
|
Locked | Mar 18 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 27 2025 |
Truist Securities |
Locked
➜
Locked
|
Locked | Jan 23 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 02 2025 |
Jefferies |
Locked
➜
Locked
|
Locked | Dec 31 2024 |
Wells Fargo |
Locked
➜
Locked
|
Locked | Dec 31 2024 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Dec 20 2024 |
Analyst Rating | Date |
---|---|
Locked
RBC Capital:
Locked
➜
Locked
|
Mar 18 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 27 2025 |
Locked
Truist Securities:
Locked
➜
Locked
|
Jan 23 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 02 2025 |
Locked
Jefferies:
Locked
➜
Locked
|
Dec 31 2024 |
Locked
Wells Fargo:
Locked
➜
Locked
|
Dec 31 2024 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Dec 20 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.